secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2023-09-22T23:59:59+00:00
Accession:  0001628280-23-032817
Event type: other
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neoleukin Therapeutics to effect 1-for-5 reverse stock split on Sept 25 to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-5 ratio effective 12:01 a.m. ET on Sept 25, 2023; ticker NLTX unchanged, new CUSIP 64049K203.
- Purpose: regain compliance with Nasdaq minimum bid price requirement of $1.00 per share.
- Outstanding shares reduced from ~44,026,429 to ~8,805,285; no fractional shares, cash paid in lieu.
- Authorized shares decreased from 100,000,000 to 20,000,000 per Certificate of Amendment filed with Delaware.
- Proportionate adjustments to exercise prices and shares underlying equity awards and pre-funded warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023032817/0001628280-23-032817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023032817/nltx-20230922.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-032817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer